Clinical trials: Non-Cirrhotic
Hepatitis C
Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus
The purpose of this study is to determine whether treatment with Daclatasvir/Asunaprevir/BMS-791325, with or without ribavirin, for 8, 6, or 4 weeks is feasible for the treatment of genotype 1a chronic hepatitis C in patients…
- Trial name
- RHACE 1 (NCT02098616)
- Testing
- DCV/ASV/BMS-791325, DCV/ASV/BMS-791325 + RBV
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Timothy Morgan, MD
Advanced Chronic Liver Disease, Surgery--Complications
Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery
The ELASTO-SURGERY study aims to evaluate the prognostic role of portal hypertension evaluated by non-invasive methods in predicting post-operative morbidity (at 90 days) and mortality (at 365 days) in patients with advanced…
- Trial name
- NCT04615091
- Where
- 37 sites in United States, Austria and 10 more
- Volunteers
- 250 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
NASH - Nonalcoholic Steatohepatitis
AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis
This is a Phase 1b multi-center, randomized, double-blind, dose-ranging, placebo-controlled, adaptive study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) of TERN-201 in patients with non-cirrhotic NASH.
- Trial name
- NCT04897594
- Testing
- TERN-201
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cirrhosis, Vascular Diseases
Endoscopic Ultrasound-Guided Portosystemic Pressure Gradient Measurements
Portal hypertension (PHT) is the main consequence of advanced chronic liver diseases (ACLD) and is often associated with severe complications leading to increased morbidity and mortality.
- Trial name
- EUSPREM (NCT06216509)
- Testing
- Endoscopic ultrasound pressure measurement
- Where
- Romania
- Volunteers
- 50 people
- Sponsor
- Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor
Non Cirrhotic Portal Hypertension
Comparison of Endoscopic Variceal Ligation (EVL) With Propranolol in Non Cirrhotic Portal Hypertension (NCPH)
Background: Variceal bleeding is a major cause of morbidity and mortality in patients with Non Cirrhotic Portal Hypertension (NCPH).
- Trial name
- NCT01000779
- Testing
- Propranolol, multi band ligator for esophageal varices
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Govind Ballabh Pant Hospital
Non-Alcoholic Steatohepatitis (NASH)
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.
- Trial name
- IMPACT (NCT05989711)
- Testing
- Pemvidutide
- Where
- 40 sites in United States, Australia and 1 more
- Volunteers
- 212 people
- Sponsor
- Altimmune, Inc.
Cirrhosis
Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics
The three objectives of this trial are: 1. To demonstrate that a decline in hepatic metabolic function as measured by BreathID will correlate with changes in CTP and MELD scores in patients with cirrhosis. 2.
- Trial name
- NCT00375011
- Where
- 3 sites in United States, Israel
- Volunteers
- 200 people
- Sponsor
- Meridian Bioscience, Inc.
Non Alcoholic Steatohepatitis (NASH)
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis…
- Trial name
- NCT04880187
- Testing
- AXA1125
- Where
- 75 sites in United States, Australia and 5 more
- Volunteers
- 273 people
- Sponsor
- Axcella Health, Inc
Hepatitis C Virus Infection
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
The purpose of this study was to evaluate the efficacy and safety of co-administration of glecaprevir (ABT-493)/pibrentasvir (ABT 530) plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 …
- Trial name
- MAGELLAN-3 (NCT02939989)
- Testing
- Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 33 people
- Sponsor
- AbbVie
Hepatic Encephalopathy
A Retrospective, Open-label, Uncontrolled Cohort Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West Haven Criteria) Hepatic Encephalopathy (HE) [The RETRO Study]
This is a retrospective study in adult patients with cirrhosis and grade 3 or 4 HE (West Haven Criteria) to evaluate the effectiveness and safety of lactulose retention enema in the treatment of deep grade HE (West Haven…
- Trial name
- NCT02377947
- Where
- 3 sites in India
- Volunteers
- 50 people
- Sponsor
- Abbott
Chronic Hepatitis C Virus Infection
Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients
enrolled participants were treated orally with SOF plus a fixed dose combination of OBV/PTV/r plus RBV.
- Trial name
- NCT04391985
- Testing
- SOF plus (OBV/PTV/r) plus RBV
- Where
- Egypt
- Volunteers
- 113 people
- Sponsor
- Beni-Suef University
Hepatic Insufficiency
Hepato Biliary Scintigraphy to Assess the Risk of Postoperative Liver Failure Hepatectomies
Extended hepatectomies of 4 or more segments are complicated by high rates of morbidity and mortality, mainly related to hepatic liver failure.
- Trial name
- SCINTIVOL (NCT02753517)
- Testing
- Hepatobiliary scintigraphy
- Where
- 12 sites in France
- Volunteers
- 326 people
- Sponsor
- University Hospital, Lille
Hepatitis C, Non-Alcoholic Fatty Liver Disease
Phase I Trial of Silymarin for Chronic Liver Diseases
The purpose of this study is to determine the safety and tolerability of different dosages of silymarin on subjects with Hepatitis C or Non-Alcoholic Fatty Liver Disease.
- Trial name
- SyNCH (NCT00389376)
- Testing
- Silymarin
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Non-Cirrhotic Portal Hypertension, Common Variable Immunodeficiency
Prediction of Portal Hypertension in Patients With CVID (CVID-pHT)
Patients with CVID will be offered to participate in this observational trial during the routine annual visit in the outpatient clinic at the Center of chronic Immunodeficiency (CCI) of the University Medical Center Freiburg…
- Trial name
- CVID-pHT (NCT06145100)
- Testing
- Ultrasound including color doppler ultrasound
- Where
- Germany
- Volunteers
- 250 people
- Sponsor
- University Hospital Freiburg
Chronic Hepatitis C
Monitoring of Hepatitis C Treatment Using Telemedicine - a Clinical Trial in Public Health System in Brazil
The study is a non-randomized, single group clinical trial on monitoring hepatitis C therapy using telemedicine. Patients with chronic hepatitis C without cirrhosis will be treated with the pangenotypic regimen of direct acting…
- Trial name
- NCT04039698
- Testing
- Telemedicine, Velpatasvir/Sofosbuvir
- Where
- Brazil
- Volunteers
- 144 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Hepatitis C
UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects
To demonstrate the effectiveness of DCV 3DAA fixed dose regimen in treatment naive and treatment experienced non-cirrhotic subjects
- Trial name
- NCT01979939
- Testing
- DCV/ASV/BMS-791325
- Where
- 66 sites in United States, Australia and 3 more
- Volunteers
- 416 people
- Sponsor
- Bristol-Myers Squibb
Hepatocellular Carcinoma, HCC
HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation
All international guidelines recommend 6-monthly ultrasound surveillance for patients at risk for liver cancer (hepatocellular carcinoma or HCC), such as patients with cirrhosis.
- Trial name
- NCT04455932
- Testing
- Abbreviated non-contrast MRI of the liver, Ultrasound surveillance, Multiphase contrast-enhanced liver MRI
- Where
- 10 sites in Australia, New Zealand
- Volunteers
- 476 people
- Sponsor
- Concord Repatriation General Hospital
NASH, MASH
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)
This is a Phase 2a study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin [softgel] capsule) for 12 weeks.
- Conditions
- NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis
- Trial name
- HERALD (NCT06342947)
- Testing
- ALG-055009
- Where
- 40 sites in United States
- Volunteers
- 102 people
- Sponsor
- Aligos Therapeutics
Portal Hypertension
Risk Factors for Variceal Bleeding in Egyptian Patients With Non-Cirrhotic Portal Hypertension
Background \& Aims: Non-cirrhotic portal hypertension (NCPH) represents a relatively infrequent group of conditions. This work aimed at determining causes of NCPH and evaluating the role of some clinical, laboratory, imaging and…
- Trial name
- NCT02635815
- Testing
- Upper gastrointestinal endoscopy
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Cirrhosis, Portal Hypertension
Hepatic Venous Pressure Gradient Versus Endoscopic Ultrasound-Guided Portal Pressure Gradient - Comparative Analysis (HEPCA)
The goal of this interventional trial is to compare in measuring of portal hypertension by HVPG and EUS-PPG in subject indicated to HVPG measurement.
- Conditions
- Cirrhosis, Portal Hypertension, EUS, Non-Cirrhotic Portal Hypertension
- Trial name
- HEPCA (NCT07424963)
- Testing
- Hepatic venous pressure gradient measurement, Endoscopic ultrasound-guided portal pressure gradient measurement
- Where
- 2 sites in Czechia
- Volunteers
- 40 people
- Sponsor
- Military University Hospital, Prague